Emmanuel Tsoupanarias - Manhattan Scients Chairman
| MHTX Stock | USD 0.0008 0.0001 11.11% |
Chairman
Mr. Emmanuel Tsoupanarias is President, Chief Executive Officer of the Company. He has served as our chief executive officer and chairman of the Board since November 1, 2007 since 2015.
| Age | 70 |
| Tenure | 9 years |
| Phone | 212 541 2405 |
| Web | https://www.mhtx.com |
Manhattan Scients Management Efficiency
The company has return on total asset (ROA) of (0.1724) % which means that it has lost $0.1724 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.5111) %, meaning that it created substantial loss on money invested by shareholders. Manhattan Scients' management efficiency ratios could be used to measure how well Manhattan Scients manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Eric Weisblum | Silo Pharma | 54 | |
| MD MPH | Mineralys Therapeutics, Common | 47 | |
| Mark Emalfarb | Dyadic International | 68 | |
Management Performance
| Return On Equity | -2.51 | |||
| Return On Asset | -0.17 |
Manhattan Scients Leadership Team
Elected by the shareholders, the Manhattan Scients' board of directors comprises two types of representatives: Manhattan Scients inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Manhattan. The board's role is to monitor Manhattan Scients' management team and ensure that shareholders' interests are well served. Manhattan Scients' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Manhattan Scients' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leonard Friedman, Secretary and Director | ||
| Emmanuel Tsoupanarias, Chairman, CEO and President and Principal Accounting Officer | ||
| Marvin Maslow, Founder, Director and Chairman of Tamarack Storage Devices Inc | ||
| Robert Proulx, Pres Imagion |
Manhattan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Manhattan Scients a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.51 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (13.38) % | |||
| Current Valuation | 4.33 M | |||
| Shares Outstanding | 559.28 M | |||
| Shares Owned By Insiders | 18.63 % | |||
| Shares Owned By Institutions | 0.30 % | |||
| Price To Earning | 1.35 X | |||
| Price To Book | 15.64 X | |||
| Price To Sales | 99.55 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Manhattan Pink Sheet Analysis
When running Manhattan Scients' price analysis, check to measure Manhattan Scients' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Manhattan Scients is operating at the current time. Most of Manhattan Scients' value examination focuses on studying past and present price action to predict the probability of Manhattan Scients' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Manhattan Scients' price. Additionally, you may evaluate how the addition of Manhattan Scients to your portfolios can decrease your overall portfolio volatility.